174 related articles for article (PubMed ID: 30618524)
1. Efficacy of diphenylcyclopropenone in alopecia areata: a comparison of two treatment regimens.
Nowicka D; Maj J; Jankowska-Konsur A; Hryncewicz-Gwóźdź A
Postepy Dermatol Alergol; 2018 Dec; 35(6):577-581. PubMed ID: 30618524
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of anthralin in combination with diphenylcyclopropenone in the treatment of alopecia areata: a retrospective case series.
Nasimi M; Ghandi N; Abedini R; Mirshamsi A; Shakoei S; Seirafi H
Arch Dermatol Res; 2019 Oct; 311(8):607-613. PubMed ID: 31165933
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of diphenylcyclopropenone alone or in combination with anthralin in the treatment of chronic extensive alopecia areata: a retrospective case series.
Durdu M; Özcan D; Baba M; Seçkin D
J Am Acad Dermatol; 2015 Apr; 72(4):640-50. PubMed ID: 25653027
[TBL] [Abstract][Full Text] [Related]
4. A prospective comparative study of two regimens of diphenylcyclopropenone (DPCP) in the treatment of alopecia areata.
Al Bazzal A; Hatami P; Abedini R; Etesami I; Ayanian Z; Ghandi N
Int Immunopharmacol; 2021 Dec; 101(Pt B):108186. PubMed ID: 34710658
[TBL] [Abstract][Full Text] [Related]
5. A randomized trial of diphenylcyclopropenone (DPCP) combined with anthralin versus DPCP alone for treating moderate to severe alopecia areata.
Ghandi N; Daneshmand R; Hatami P; Abedini R; Nasimi M; Aryanian Z; Vance TM
Int Immunopharmacol; 2021 Oct; 99():107971. PubMed ID: 34298402
[TBL] [Abstract][Full Text] [Related]
6. Treatment Response to Diphenylcyclopropenone in Patients with Alopecia Totalis/Universalis.
Varghese SA; Nair SS; George AE; Yadev I
Int J Trichology; 2023; 15(4):149-153. PubMed ID: 38765726
[TBL] [Abstract][Full Text] [Related]
7. A retrospective comparative study of the efficacy and safety of two regimens of diphenylcyclopropenone in the treatment of recalcitrant alopecia areata.
Sriphojanart T; Khunkhet S; Suchonwanit P
Dermatol Reports; 2017 Oct; 9(2):7399. PubMed ID: 29299216
[TBL] [Abstract][Full Text] [Related]
8. Is the severity of initial sensitization to diphenylcyclopropenone in alopecia areata patients predictive of the final clinical response?
Ghandi N; Seifi G; Nasimi M; Abedini R; Mirabedian S; Etesami I; Ehsani A
Dermatol Ther; 2021 Nov; 34(6):e15118. PubMed ID: 34464020
[TBL] [Abstract][Full Text] [Related]
9. Diphenylcyclopropenone and platelet-rich plasma in the management of severe or recalcitrant alopecia areata.
Abd El-Magid WM; Mohamed RA; Elsharkawy RE
J Cosmet Dermatol; 2023 Nov; 22(11):2971-2981. PubMed ID: 37313640
[TBL] [Abstract][Full Text] [Related]
10. Topical immunotherapy with diphenylcyclopropenone in the treatment of chronic extensive alopecia areata.
Sotiriadis D; Patsatsi A; Lazaridou E; Kastanis A; Vakirlis E; Chrysomallis F
Clin Exp Dermatol; 2007 Jan; 32(1):48-51. PubMed ID: 17004987
[TBL] [Abstract][Full Text] [Related]
11. Topical immunotherapy of severe alopecia areata with diphenylcyclopropenone (DPCP): experience in an Iranian population.
Aghaei S
BMC Dermatol; 2005 May; 5():6. PubMed ID: 15918897
[TBL] [Abstract][Full Text] [Related]
12. Topical immunotherapy in combination with anthralin in the treatment of refractory alopecia areata.
Kagami S; Kishi Y; Hino H
J Cosmet Dermatol; 2020 Sep; 19(9):2411-2414. PubMed ID: 32621407
[TBL] [Abstract][Full Text] [Related]
13. Serum level of IL-4 predicts response to topical immunotherapy with diphenylcyclopropenone in alopecia areata.
Gong Y; Zhao Y; Zhang X; Qi S; Li S; Ye Y; Yang J; Caulloo S; McElwee KJ; Zhang X
Exp Dermatol; 2020 Mar; 29(3):231-238. PubMed ID: 30047620
[TBL] [Abstract][Full Text] [Related]
14. Hair Regrowth Outcomes of Contact Immunotherapy for Patients With Alopecia Areata: A Systematic Review and Meta-analysis.
Lee S; Kim BJ; Lee YB; Lee WS
JAMA Dermatol; 2018 Oct; 154(10):1145-1151. PubMed ID: 30073292
[TBL] [Abstract][Full Text] [Related]
15. Clinical Efficacy of Diphenylcyclopropenone in Alopecia Areata: Retrospective Data Analysis of 50 Patients.
Chiang KS; Mesinkovska NA; Piliang MP; Bergfeld WF
J Investig Dermatol Symp Proc; 2015 Nov; 17(2):50-5. PubMed ID: 26551948
[TBL] [Abstract][Full Text] [Related]
16. Treatment of chronic extensive alopecia areata by diphenylcyclopropenone alone versus in combination with anthralin.
Ibrahim SA; Esawy AM; Abdelshafy AS
Dermatol Ther; 2019 Sep; 32(5):e13010. PubMed ID: 31237076
[TBL] [Abstract][Full Text] [Related]
17. Economic Impact of Home-Use versus Office-Use Diphenylcyclopropenone in Extensive Alopecia Areata.
Lekhavat C; Rattanaumpawan P; Juengsamranphong I
Skin Appendage Disord; 2022 Mar; 8(2):108-117. PubMed ID: 35419425
[TBL] [Abstract][Full Text] [Related]
18. The use of topical diphenylcyclopropenone for the treatment of extensive alopecia areata.
Cotellessa C; Peris K; Caracciolo E; Mordenti C; Chimenti S
J Am Acad Dermatol; 2001 Jan; 44(1):73-6. PubMed ID: 11148480
[TBL] [Abstract][Full Text] [Related]
19. Assessment of treatment efficacy of diphenylcyclopropenone (DPCP) for alopecia areata.
Kutlubay Z; Sevim A; Aydın Ö; Vehid S; Serdaroğlu S
Turk J Med Sci; 2020 Dec; 50(8):1817-1824. PubMed ID: 31655499
[TBL] [Abstract][Full Text] [Related]
20. Randomized controlled trial to compare the effectiveness and safety of low dose dexamethasone oral mini-pulse versus diphenylcyclopropenone contact sensitisation in severe pediatric alopecia areata.
Mahajan R; Daroach M; Handa S; De D
Dermatol Ther; 2022 Nov; 35(11):e15810. PubMed ID: 36086930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
